Schneyer Mark C.'s Form 4 filing
Acadia Pharmaceuticals Inc (ACAD) · filed Aug 20, 2024
- Accession no.
- 0001415889-24-021731
- Filed
- Aug 20, 2024
- Trade date
- Aug 16-19, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $148.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schneyer Mark C.CIK 0001899977 | Officer (EVP, CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2024 | Common Stock | AGrant or awardAcquired | +5,275 | $0.00F1 | $0 | 39,839 | Direct | |
| Aug 16, 2024 | Common Stock | AGrant or awardAcquired | +13,629 | $0.00F2 | $0 | 53,468 | Direct | |
| Aug 19, 2024 | Common Stock | SSaleDisposed | −9,733 | $15.28F4 | −$148,720.24 | 43,735 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target.
Referenced by the price of 1 transaction in Table I.
- F2
Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Referenced by the price of 1 transaction in Table I.